Good day for announcements today, a UK company have announced initial testing results of an
"inhaled formulation of interferon beta in hospitalised COVID-19 patients. A replay of the webinar hosted 20 July is available to view here.
"The Phase II double-blind placebo-controlled trial called SG016 recruited 101 patients from 9 specialists sites in the UK during the period 30 March to 27 May 2020 and found that patients receiving SNG001 had a 79% lower risk of developing severe disease compared to placebo and additionally that patients who received SNG001 were more than twice as likely to recover from COVID-19 as those on placebo."
www.synairgen.com/
Their shares went up over 500%!!
|